

Erratum to: In situ validation of VEGFR-2 and $\alpha_v\beta_3$ integrin as targets for breast lesion characterization

Josef Ehling^{1,2} · Matthias Misiewicz¹ · Saskia von Stillfried² · Diana Möckel¹ ·
Jessica Bzyl¹ · Sibylle Pochon³ · Wiltrud Lederle¹ · Ruth Knuechel² ·
Twan Lammers^{1,4,5} · Moritz Palmowski¹ · Fabian Kiessling¹

Published online: 30 March 2016
© Springer Science+Business Media Dordrecht 2016

Erratum to: *Angiogenesis* DOI 10.1007/s10456-016-9499-4

“Josef Ehling and Matthias Misiewicz have contributed equally to this work.”

In the original publication of the article, the author missed to insert the equal first authorship as an article note. However, the article note above the affiliation should be

Josef Ehling and Matthias Misiewicz have contributed equally to this work.

The online version of the original article can be found under doi:[10.1007/s10456-016-9499-4](https://doi.org/10.1007/s10456-016-9499-4).

✉ Fabian Kiessling
fkiessling@ukaachen.de

- ¹ Department for Experimental Molecular Imaging, Helmholtz Institute for Biomedical Engineering, Medical Faculty, RWTH Aachen University, Pauwelsstr. 30, 52074 Aachen, Germany
- ² Institute of Pathology, Medical Faculty, RWTH Aachen University, Aachen, Germany
- ³ Bracco Suisse SA, Geneva, Switzerland
- ⁴ Department of Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands
- ⁵ Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands